Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 41 (GAPDHP41) is a non-coding processed pseudogene in the human genome that shows high sequence homology to the coding gene for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an essential glycolytic enzyme[1][2][3]. This pseudogene was likely generated by retrotransposition—copying of an mRNA back into the genome without a functional coding capacity and contains sequence disablements (mutations) that prevent it from producing functional protein[2][3]. Processed pseudogenes like GAPDHP41 are abundant in the human and mouse genomes and reflect evolutionary history, arising most often from highly expressed housekeeping genes like GAPDH[3]. GAPDHP41 does not have a current known biological function, does not produce a functional protein, and is not implicated in therapeutic targeting, disease, or drug interaction[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 41 (GAPDHP41).